Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2112958 | 0.83 | TAAR1 (0.42) | NOTUM | |
| SCHEMBL1134861 | 0.81 | — | — | |
| SCHEMBL694755 | 0.80 | ACHE (0.34) | — | |
| SCHEMBL9646719 | 0.78 | ACHE (0.32) | — | |
| SCHEMBL4453497 | 0.76 | NOTUM (0.32) | CYP1A2CYP2A6NOTUM | |
| SCHEMBL2449602 | 0.76 | ALDH1A1 (0.41) | CYP1A2CYP2A6NOTUM | |
| SCHEMBL1134830 | 0.75 | MAOB (0.38) | CYP1A2NOTUM | |
| SCHEMBL5326217 | 0.75 | ACHE (0.39) | — | |
| SCHEMBL6705304 | 0.74 | ACHE (0.35) | CYP1A2CYP2A6 | |
| SCHEMBL17046416 | 0.74 | ALDH1A1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691857-B2 | Muscarinic agents as therapeutic compounds | MUSCAGEN LIMITED (GB) | 2010-04-06 | — | — | US | claimed |
| CN-111406059-B | Europium complexes | 东曹株式会社 | 2023-04-18 | — | — | CN | disclosed |
| US-10988494-B2 | Europium complex | TOSOH CORPORATION (JP) | 2021-04-27 | — | — | US | disclosed |
| US-20200354389-A1 | EUROPIUM COMPLEX | SAGAMI CHEMICAL RESEARCH INSTITUTE (JP) | 2020-11-12 | — | — | US | disclosed |
| EP-1697359-B1 | MUSCARINIC AGONISTS AS THERAPEUTIC COMPOUNDS | MUSCAGEN LTD (GB) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988494-B2 | Europium complex | SSB, XPA, UACA | CYP1A2 1130/4885CYP2A6 1000/4885CNR1 315/4885 |
| US-20200354389-A1 | EUROPIUM COMPLEX | SSB, XPA, UACA | CYP1A2 1130/4885CYP2A6 1000/4885CNR1 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.